Parkinson's disease
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Parkinson's disease
- In this situation, no routine laboratory test is recommended
- Vitamin B12if needednon-French guidelineThe German recommendation (DGN 2023, S2k expert consensus) asks, before starting levodopa-carbidopa intestinal gel by pump, for an electrophysiological search for neuropathy and measurement of vitamins B6, B12 and folate, checked thereafter throughout treatment and corrected if low [2]. The HAS guide (2016) does not address this point [1].
- Folateif needednon-French guidelineThe German recommendation (DGN 2023, S2k expert consensus) asks, before starting levodopa-carbidopa intestinal gel by pump, for an electrophysiological search for neuropathy and measurement of vitamins B6, B12 and folate, checked thereafter throughout treatment and corrected if low [2]. The HAS guide (2016) does not address this point [1].
- Vitamin B6if needednon-French guidelineThe German recommendation (DGN 2023, S2k expert consensus) asks, before starting levodopa-carbidopa intestinal gel by pump, for an electrophysiological search for neuropathy and measurement of vitamins B6, B12 and folate, checked thereafter throughout treatment and corrected if low [2]. The HAS guide (2016) does not address this point [1].
Before and during an ergot-derived dopamine agonist (bromocriptine, lisuride)
Laboratory tests
- Serum creatinine with eGFR
- CRP (marker of inflammation)
- Not a laboratory test: echocardiography (valvular disease), pulmonary function tests, chest X-ray.
Parkinsonism in a young patient: Wilson's disease
Laboratory tests
- Caeruloplasmin
- Serum copper
- 24-hour urinary copper
- ASTif needednon-French guidelineThe summary of the American recommendation (AASLD 2022) pairs, to investigate suspected Wilson's disease, liver function tests, an FBC and an INR with caeruloplasmin and 24-hour urinary copper [8]. The HAS guide cites liver involvement and confirms the diagnosis by copper studies [1]. In France, the prothrombin time code outside vitamin K antagonist treatment also gives the INR where relevant [5].
- ALTif needednon-French guidelineThe summary of the American recommendation (AASLD 2022) pairs, to investigate suspected Wilson's disease, liver function tests, an FBC and an INR with caeruloplasmin and 24-hour urinary copper [8]. The HAS guide cites liver involvement and confirms the diagnosis by copper studies [1]. In France, the prothrombin time code outside vitamin K antagonist treatment also gives the INR where relevant [5].
- FBCif needednon-French guidelineThe summary of the American recommendation (AASLD 2022) pairs, to investigate suspected Wilson's disease, liver function tests, an FBC and an INR with caeruloplasmin and 24-hour urinary copper [8]. The HAS guide cites liver involvement and confirms the diagnosis by copper studies [1]. In France, the prothrombin time code outside vitamin K antagonist treatment also gives the INR where relevant [5].
- PTif needednon-French guidelineThe summary of the American recommendation (AASLD 2022) pairs, to investigate suspected Wilson's disease, liver function tests, an FBC and an INR with caeruloplasmin and 24-hour urinary copper [8]. The HAS guide cites liver involvement and confirms the diagnosis by copper studies [1]. In France, the prothrombin time code outside vitamin K antagonist treatment also gives the INR where relevant [5].
Sources (8)
- GUIDE DU PARCOURS DE SOINS Maladie de Parkinson
- Höglinger G, et al.; German Parkinson's Guidelines Committee. Diagnosis and treatment of Parkinson's disease (guideline of the German Society for Neurology). Neurol Res Pract. 2024;6(1):30 (version abrégée en anglais de la recommandation S2k de la DGN, AWMF 030/010, mise à jour du 30 novembre 2023).
- National Institute for Health and Care Excellence (NICE). Parkinson's disease in adults. Guideline NG71, 19 juillet 2017.
- Gazewood JD, Richards DR, Clebak K. Parkinson disease: an update. Am Fam Physician. 2013;87(4):267-273.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0547 (cuivre sérique), 1809 (céruléoplasmine), 2008 (cuivre urinaire) ; absence d'acte actif pour la vitesse de sédimentation.
- ANSM. Résumé des caractéristiques du produit PARLODEL 10 mg, gélule (bromocriptine), rubriques 4.1, 4.3 et 4.4 ; base de données publique des médicaments, page « extrait » consultée le 13/10/2026 (mise à jour du 29/09/2026).
- Medicines and Healthcare products Regulatory Agency (MHRA). Ergot-derived dopamine agonists: risk of fibrosis. Drug Safety Update, juillet 2008, vol. 1, n° 12, p. 9 (mis en ligne sur gov.uk le 11 décembre 2014).
- Alkhouri N, Gonzalez-Peralta RP, Medici V. Wilson disease: a summary of the updated AASLD Practice Guidance. Hepatol Commun. 2023;7(6):e0150.